Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trevor Hawkins

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2024
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized TrialYing Liu, Jacquelyn Bainbridge, Stefan Sillau, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotypeMatthew W State, John M Greally, Adam Cuker, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Genome Research|October 9, 2002
Draft sequencing and comparative genomics of Xylella fastidiosa strains reveal novel biological insightsAnamitra Bhattacharyya, Stephanie Stilwagen, Gary Reznik, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Advanced Therapeutics|May 17, 2021
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primatesFernanda P Pons-Faudoa, Antons Sizovs, Kathryn A Shelton, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
Cerebellum (London, England)|January 2, 2024
The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar AtaxiasLouisa P Selvadurai, Susan L Perlman, Tetsuo Ashizawa, et al.
Brain : a Journal of Neurology|October 28, 2025
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3Emilien Petit, Giulia Coarelli, David Morgan, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2024
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized TrialYing Liu, Jacquelyn Bainbridge, Stefan Sillau, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2003
Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotypeMatthew W State, John M Greally, Adam Cuker, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Genome Research|October 9, 2002
Draft sequencing and comparative genomics of Xylella fastidiosa strains reveal novel biological insightsAnamitra Bhattacharyya, Stephanie Stilwagen, Gary Reznik, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Advanced Therapeutics|May 17, 2021
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primatesFernanda P Pons-Faudoa, Antons Sizovs, Kathryn A Shelton, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
Cerebellum (London, England)|January 2, 2024
The Cerebellar Cognitive Affective/Schmahmann Syndrome Scale in Spinocerebellar AtaxiasLouisa P Selvadurai, Susan L Perlman, Tetsuo Ashizawa, et al.
Brain : a Journal of Neurology|October 28, 2025
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3Emilien Petit, Giulia Coarelli, David Morgan, et al.
Pageof 4